menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

KOL KNOCKOUT™: Endocrinology Edition – Thyroid Titans Clash to Enhance Outcomes in Thyroid Eye Disease – Round 3

Endocrinology’s top minds clash in this game show-style CME, hosted by Malini Gupta, MD, FACE, ECNU. Who will be crowned champion?

Live Broadcast
1.50 available credits
Information
April 08, 2024
08:00 PM - 09:30 PM EDT
Virtual
ReachMD Healthcare Image
Details
Presenters
  • Overview

    Get ready for the exciting finale of KOL Knockout: Endocrinology Edition! Led by chair Malini Gupta, MD, FACE, ECNU, thyroid experts Sonalika Khachikian, MD; John Woody Sistrunk, MD; and Round 2 winner Kaniksha Desai, MD, FACE, ECNU, will analyze cases of thyroid dysfunction and thyroid eye disease (TED). Gain valuable insights as they discuss clinical signs and symptoms, diagnosis, and management strategies. Join us for some friendly (but fierce) rivalry as they navigate complex case scenarios.

  • Disclosure of Conflicts of Interest

    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

    The following faculty/staff members have the following financial relationships with ineligible companies.

    Host:
    Malini Gupta, MD, ECNU, FACE, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Abbvie, Creative Consultant. Speaker's Bureau: IBSA and Horizon. Owner/Employee: G2Endo/Consolidated Medical Practices of Memphis.

    Faculty:
    Kaniksha Desai MD, ECNU, FACE,
     has had no financial relationships with ineligible companies.

    Sonalika Khachikian, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Amgen, Amneal Pharmaceuticals, and Novo Nordisk. Speaker’s Bureau: Amgen.

    John Woody Sistrunk, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Interpace Diagnostics.

    The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Diagnose thyroid eye disease (TED) based on clinical examination and appropriate testing, to enable assessment of disease activity, severity, and impact on quality of life
    • Appraise the risk-benefit profile of medical and biological therapies for TED
    • Devise individualized treatment plans for patients with varying degrees of TED activity and severity that prevent disease progression
    • Establish referral and comanagement protocols that ensure patient access to specialized and collaborative care
  • Target Audience

    This certified continuing education activity is designed for endocrinologists and endocrine care providers involved in the care of patients with thyroid eye disease.

  • Accreditation and Credit Designation Statements

    Provided by Evolve Medical Education 

    Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Evolve designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

  • Grantor Statement

    This activity is supported by an unrestricted educational grant from Horizon Therapeutics.

  • Disclaimer

    OFF-LABEL STATEMENT
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Horizon Therapeutics.

    This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Details
Presenters
Recommended
  • Overview

    Get ready for the exciting finale of KOL Knockout: Endocrinology Edition! Led by chair Malini Gupta, MD, FACE, ECNU, thyroid experts Sonalika Khachikian, MD; John Woody Sistrunk, MD; and Round 2 winner Kaniksha Desai, MD, FACE, ECNU, will analyze cases of thyroid dysfunction and thyroid eye disease (TED). Gain valuable insights as they discuss clinical signs and symptoms, diagnosis, and management strategies. Join us for some friendly (but fierce) rivalry as they navigate complex case scenarios.

  • Disclosure of Conflicts of Interest

    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

    The following faculty/staff members have the following financial relationships with ineligible companies.

    Host:
    Malini Gupta, MD, ECNU, FACE, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Abbvie, Creative Consultant. Speaker's Bureau: IBSA and Horizon. Owner/Employee: G2Endo/Consolidated Medical Practices of Memphis.

    Faculty:
    Kaniksha Desai MD, ECNU, FACE,
     has had no financial relationships with ineligible companies.

    Sonalika Khachikian, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Amgen, Amneal Pharmaceuticals, and Novo Nordisk. Speaker’s Bureau: Amgen.

    John Woody Sistrunk, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Interpace Diagnostics.

    The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Diagnose thyroid eye disease (TED) based on clinical examination and appropriate testing, to enable assessment of disease activity, severity, and impact on quality of life
    • Appraise the risk-benefit profile of medical and biological therapies for TED
    • Devise individualized treatment plans for patients with varying degrees of TED activity and severity that prevent disease progression
    • Establish referral and comanagement protocols that ensure patient access to specialized and collaborative care
  • Target Audience

    This certified continuing education activity is designed for endocrinologists and endocrine care providers involved in the care of patients with thyroid eye disease.

  • Accreditation and Credit Designation Statements

    Provided by Evolve Medical Education 

    Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Evolve designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

  • Grantor Statement

    This activity is supported by an unrestricted educational grant from Horizon Therapeutics.

  • Disclaimer

    OFF-LABEL STATEMENT
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Horizon Therapeutics.

    This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Schedule24 Apr 2024